المؤلفون: Kyoko Ito, Yuko Mitobe, Ryo Inoue, Mikio Momoeda

المصدر: BMC Women's Health, Vol 23, Iss 1, Pp 1-11 (2023)

مصطلحات موضوعية: Iron preparations, Nausea, Vomiting, EQ-5D-5L utility scores, Heavy menstrual bleeding, Anemia, Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1472-6874Test

الوصول الحر: https://doaj.org/article/b4a57e2b8afe43bd8fee369e4cc1fb44Test

المؤلفون: Derman, Richard J., Patted, Anmol

المصدر: Global Health Articles

مصطلحات موضوعية: anemia, heavy menstrual bleeding, hemorrhage, intravenous iron supplementation, iron deficiency, iron deficiency anemia, Female, Pregnancy, Humans, Iron-Deficiency, Iron Deficiencies, Iron, Menorrhagia, Hematology, Medicine and Health Sciences, Women's Health

وصف الملف: application/pdf

العلاقة: https://jdc.jefferson.edu/gha/30Test; https://jdc.jefferson.edu/context/gha/article/1029/viewcontent/Intl_J_Gynecology___Obste___2023___Derman.pdfTest

الإتاحة: https://jdc.jefferson.edu/gha/30Test
https://jdc.jefferson.edu/context/gha/article/1029/viewcontent/Intl_J_Gynecology___Obste___2023___Derman.pdfTest

المؤلفون: Dominika Zajdel, Paula Jankowska

المصدر: Journal of Education, Health and Sport, Vol 13, Iss 1 (2022)

مصطلحات موضوعية: heavy menstrual bleeding, bleeding disorders, adolescents, anemia, Education, Sports, GV557-1198.995, Medicine

وصف الملف: electronic resource

العلاقة: https://apcz.umk.pl/JEHS/article/view/40867Test; https://doaj.org/toc/2391-8306Test

الوصول الحر: https://doaj.org/article/a7d29e1348c64bbea475fa2a9873ef9dTest

المؤلفون: Z. V. Revazova, L. V. Adamyan, O. N. Loginova, L. M. Manukyan, K. N. Arslanyan

المصدر: Акушерство, гинекология и репродукция, Vol 15, Iss 1, Pp 80-92 (2021)

مصطلحات موضوعية: uterine myoma, fibroid, myomectomy, heavy menstrual bleeding, anemia, myoma treatment, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

العلاقة: https://www.gynecology.su/jour/article/view/866Test; https://doaj.org/toc/2313-7347Test; https://doaj.org/toc/2500-3194Test

الوصول الحر: https://doaj.org/article/ea4b9a8df9184d30b1c1950de1b84490Test

المؤلفون: Carter-Febres, Maria, Fenchel, Matthew, Pomales, Jennifer, Tarango, Cristina, Mullins, Eric S

المصدر: Thromb Res ; ISSN:1879-2472 ; Volume:240

مصطلحات موضوعية: Anemia, Heavy menstrual bleeding, Von willebrand factor

العلاقة: https://doi.org/10.1016/j.thromres.2024.109061Test; https://pubmed.ncbi.nlm.nih.gov/38870771Test

الإتاحة: https://doi.org/10.1016/j.thromres.2024.109061Test
https://pubmed.ncbi.nlm.nih.gov/38870771Test

المؤلفون: Zajdel, Dominika, Jankowska, Paula

المصدر: Journal of Education, Health and Sport; Tom 13 Nr 1 (2023); 246-250 ; Journal of Education, Health and Sport; Vol. 13 No. 1 (2023); 246-250 ; 2391-8306

مصطلحات موضوعية: heavy menstrual bleeding, bleeding disorders, adolescents, anemia

وصف الملف: application/pdf

العلاقة: https://apcz.umk.pl/JEHS/article/view/40867/33916Test; https://apcz.umk.pl/JEHS/article/view/40867Test

الإتاحة: https://apcz.umk.pl/JEHS/article/view/40867Test

المؤلفون: Petraglia, Felice, Dolmans, Marie-Madeleine

المساهمون: UCL - SSS/IREC/GYNE - Pôle de Gynécologie, UCL - (SLuc) Service de gynécologie et d'andrologie, UCL - (SLuc) Centre de theÌrapie tissulaire et cellulaire

المصدر: Fertility and sterility, Vol. 118, no. 4, p. 605-606 (2022)

مصطلحات موضوعية: Anemia, Iron-Deficiency, Female, Humans, Iron, Iron Deficiencies, Menorrhagia, Pregnancy, Quality of Life, Reproductive Health, Women's Health, heavy menstrual bleeding, iron deficiency, reproduction

العلاقة: boreal:272221; http://hdl.handle.net/2078.1/272221Test; info:pmid/36182259; urn:ISSN:0015-0282; urn:EISSN:1556-5653

الإتاحة: https://doi.org/10.1016/j.fertnstert.2022.08.850Test
http://hdl.handle.net/2078.1/272221Test

المؤلفون: Z. Revazova V., L. Adamyan V., O. Loginova N., L. Manukyan M., K. Arslanyan N., З. Ревазова В., Л. Адамян В., О. Логинова Н., Л. Манукян М., К. Арсланян Н.

المساهمون: The work was carried out with the financial support of the grant of the President of the Russian Federation for state support of young Russian scientists № MK-2836.2019.7 on the topic "Clinical and morphological substantiation of new possibilities for the management of patients with uterine fibroids accompanied by heavy menstrual bleeding"., Работа проведена при финансовой поддержке гранта Президента Российской Федерации для государственной поддержки молодых российских ученых № МК-2836.2019.7 на тему «Клинико-морфологическое обоснование новых возможностей ведения больных с миомой матки, сопровождающейся обильными менструальными кровотечениями».

المصدر: Obstetrics, Gynecology and Reproduction; Vol 15, No 1 (2021); 80-92 ; Акушерство, Гинекология и Репродукция; Vol 15, No 1 (2021); 80-92 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: uterine myoma, fibroid, myomectomy, heavy menstrual bleeding, anemia, myoma treatment, миома матки, лейомиома, миомэктомия, обильные менструальные кровотечения, меноррагия, анемия, медикаментозная терапия

وصف الملف: application/pdf

العلاقة: https://www.gynecology.su/jour/article/view/866/888Test; Vilos J.A., Allaire C., Laberge P.Y., Leyland N. The management of uterine leiomyomas. J Obstet Gynecol Canada. 2015;37(2):157-78. https://doi.org/10.1016/S1701-2163Test(15)30338-8.; Миома матки: диагностика, лечение и реабилитация. Клинические рекомендации. Под ред. Л.В. Адамян и др. М.: Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова, 2015. 100 с.; Islam M.S., Protic O., Giannubilo S.R. et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013;98(3):921-34. https://doi.org/10.1210/jc.2012-3237Test.; Wallach E.E., Vlahos N.F. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104(2):393-406. https://doi.org/10.1097/01.AOG.0000136079.62513.39Test.; Flake G.P., Anderson J., Dixon D. Etiology and pathophysiology of uterine leiomyomas; a review. Environ Health Perspect. 2003;111(8):1037-54. https://doi.org/10.1289/ehp.5787Test.; Lui Z., Doan Q.V., Blumenthal P., Dubois R.W. Systematic review evaluating health-related quality of life, work impairement, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183-94. https://doi.org/10.1111/j.1524-4733.2007.00168.xTest.; Буянова С.Н., Мгелиашвили М.В., Петракова С.А. Современные представления об этиологии, патогенезе и морфогенезе миомы матки. Российский вестник акушера-гинеколога. 2008;8(6):45-51.; Доброхотова Ю.Э., Хачатрян А.С., Ибрагимова Д.М. Миома матки. Современные вопросы патогенеза и медикаментозной редукционной терапии. Доктор.Ру. 2013;7—1(85):29—32.; Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393-408. https://doi.org/10.1002/ijgo.12666Test.; Андреева Е.Н. Обильные менструальные кровотечения: современный подход к проблеме и пути ее решения. Проблемы репродукции. 2015;21(6):47-55.; Dorsey K.A. Menorrhagia, active component service women, U.S. Armed Forces, 1998-2012. MSMR. 2013;20(9):20-4.; Stewart E.A., Nowak R.A. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996;2(4):295-306. https://doi.org/10.1093/humupd/2.4.295Test.; Vilos G.A., Vilos A., Ferrazzi S. Symptomatic uterine fibroids (UFs) are common in premenopausal Canadian women and lead to reduced quality of life (QoL) across multiple domains. J Obstet Gynecol Can. 2014;36:1-26.; Fonseca-Moutinho J.A., Barbosa L.S., Nunes S.M. et al. Abnormal uterine bleeding as a presenting symptom is related to multiple uterine leiomyoma: an ultrasound-based study. Int J Womens Health. 2013;5:689-94. https://doi.org/10.2147/IJWH.S50786Test.; Gokyildiz S., Aslan E., Beji N.K., Mecdi M. The effects of menorrhagia on women's quality of life: a case-control study. ISRN Obstet Gynecol. 2013;2013:918179. https://doi.org/10.1155/2013/918179Test.; Бурлев В.А., Коноводова Е.Н., Федорова Т.А., Данилов А.Ю. Диагностика и лечение железодефицитных состояний у гинекологических больных: клинический протокол. Акушерство и гинекология. 2014;(3):3-10.; Стуклов Н.И. Анемии при заболеваниях женской репродуктивной системы. Поликлиника. 2014;(3-2):87-9.; Pundir J., Walawalkar R., Seshadri S. et al. Perioperative morbidity associated with abdominal myomectomy compared with total abdominal hysterectomy for uterine fibroids. J Obstet Gynaecol. 2013;33(7):655-62. https://doi.org/10.3109/01443615.2013.816661Test.; Donnez J., Dolmans M.M. Uterine fibroids management: from the present to the future. Hum Reprod Update. 2016;22(6):665-86. https://doi.org/10.1093/humupd/dmw023Test.; Farris M., Bastianelli C., Rosato E. et al. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157-78. https://doi.org/10.2147/TCRM.S147318Test.; Пучков К.В., Андреева Ю.Е., Добычина А.В. Лапароскопическая гистерэктомия. Журнал акушерства и женских болезней. 2011;60(S):70-1.; Lefebvre G. Allaire C., Jeffrey J., Vilos G.A. Hysterectomy; Society of Obstetricians Clinical Practice Committee. SOGC Clinical Practice Guidelines. 2002;24(109):37-48. PMID: 12196887.; Flynn M., Jamison M., Datta S., Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 2006;195(4):955-64. https://doi.org/10.1016/j.ajog.2006.02.020Test.; Кулаков В.И., Адамян Л.В., Аскольская С.И. Гистерэктомия и здоровье женщины. М.: Медицина, 1999. 312 с.; Sohn G.S., Cho S., Kim Y.M. et al. Current medical treatment of uterine fibroids. Obstet Gynecol Sci. 2018;61(2):192-201. https://doi.org/10.5468/ogs.2018.61.2.192Test.; El-Balat A., DeWilde R.L., Schmeil I. et al. Modern myoma treatment in the last 20 years: a review of the literature. BioMed Research International. 2018;4:1-6. https://doi.org/10.1155/2018/4593875Test.; Ghonim M., Magby R., Sabbour M. et al. A systematic review and metaanalysis of ulipristal acetate for symptomatic uterine fibroids. Int J Gynecol Obstet. 2019;146(2):141-8. https://doi.org/10.1002/ijga.12868Test.; Eder S., Baker J., Gersten J. et al. Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids. Women's Health (Lond). 2013;9(4):397-403. https://doi.org/10.2217/whe.13.28Test.; Puchar A., Feyeux C., Luton D., Koskas M. Therapeutic management of uterine fibroid tumors. Minerva Ginecol. 2016;68(4):466-76.; Lethaby A., Duckitt K., Farquhar C. Non-steroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;(1):CD0004000. https://doi.org/10.1002/14651858.CD000400.pub3Test.; Farquhar C., Ekeroma A., Fentiman G. et al. An evidence-based guideline for the management of uterine fibroids. Aust N Z J Obstet Gynecol. 2001;41(2):125-40. https://doi.org/10.1111/j.1479-828x.2001.tb01198.xTest.; Duhan N., Madaan Sh., Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):329-32. https://doi.org/10.1016/j.ejogrb.2013.09.010Test.; Liu J.P., Yang H., Xia Yun, Cardini F. Herbal preparations for uterine fibroids. Cochrane Database Syst Rev. 2013;(4):CD005292. https://doi.org/10.1002/14651858.CD005292.pub3Test.; Song H., Lu D., Navaratnam K., Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;(10):CD009505. https://doi.org/10.1002/14651858.CD009505.pub2Test.; Федорова Т.А., Борзыкина О.М., Бакуридзе Э.М. и др. Коррекция железодефицитной анемии у пациенток с гинекологическими заболеваниями с использованием липосомального железа. Гинекология. 2017;19(1):68-73.; Whitaker L., Critchley H.O.D. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2016;34:54-65. https://doi.org/10.1016/j.bpobgyn.2015.11.012Test.; Donnez J. Uterine fibroids and progestogen treatment: lack of evidence of its efficacy: a review. J Clin Med. 2020;9(12):E3948. https://doi.org/10.3390/jcm9123948Test.; Bulun S.E., Moravek M.B., Yin P. et al. Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med. 2015;33(5):357-65. https://doi.org/10.1055/s-0035-1558451Test.; Xu Q., Ohara N., Liu J. et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14(3):181-91. https://doi.org/10.1093/molehr/gan004Test.; Maruo T., Ohara N., Wang J., Matduo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004;10(3):207-20. https://doi.org/10.1093/humupd/dmh019Test.; Socolov D., Blidaru I., Tamba B. et al. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care. 2011;16(6):480-7. https://doi.org/10.3109/13625187.2011.614028Test.; Senol T., Kahramanoglu I., Dogan Y. et al. Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma. Clin Exp Obstet Gynecol. 2015;42(2):224-7.; Islam S., Protic O., Giannubilo S.R. et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013;98(3):921-34. https://doi.org/10.1210/jc.2012-3237Test.; Tosun A.K., Tosun I., Suer N. Comparison of levonorgestrel-releasing intrauterine device with oral progestins in heavy menstrual bleeding (HMB) cases with uterine leiomyoma (LNG-IUD and oral progestin usage in myoma uteri). Pak J Med Sci. 2014;30(4):834-9.; Mittermeier Th., Farrant Ch., Wise M.R. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;9:CD012658. https://doi.org/10.1002/14651858.CD012658.pub2Test.; Sayed G.H., Zakherah M.S., El-Nashar S.A., Shaaban M.M. A randomizad clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126-30. https://doi.org/10.1016/j.ijgo.2010.08.009Test.; Тихомиров А.Л., Леденкова А.А., Абышева В.Г., Шаркова С.М. Гормональная контрацепция и профилактика миомы матки. Вопросы гинекологии, акушерства и перинатологии. 2009;8(6):71-5.; Lethaby A., Puscasiu L., Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11(11):CD000547. https://doi.org/10.1002/14651858.CD000547.pub2Test.; Doherty L., Mutlu L., Sinclair D., Taylor H. Uterine fibroids: clinical manifestations and contemporary management. Reprod Sci. 2014;21(9):1067-92. https://doi.org/10.1177/1933719114533728Test.; Camanni M., Bonino E.M., Delpiano A. et al. Hysteroscopic management of large symptomatic submucous uterine myomas. J Minim Invasive Gynecol. 2010;17(1):59-65. https://doi.org/10.1016/j.jmig.2009.10.013Test.; Guo X.C., Segars J.H. The impact and management of fibroids for fertility: an evidence-based approach. Obstet Gynecol Clin North Am. 2012;39(4):521-33. https://doi.org/10.1016/j.ogc.2012.09.005Test.; Moroni R.M., Martins W.P., Ferriani R.A. et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015(3):CD010854. https://doi.org/10.1002/14651858.CD010854.pub2Test.; Griffiths A.N., D'Angelo A., Amso N.N. Surgical treatment of fibroids for subfertility. Cochrane Database Syst Rev. 2006;(3):CD003857. https://doi.org/10.1002/14651858.CD003857.pub2Test.; Bouchard P., Chabbert-Buffet N., Fauser B.C. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175-89. https://doi.org/10.1016/j.fertnstert.2011.08.021Test.; Chabbert-Buffet N., Pintiaux A., Bouchard P. The imminent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol. 2012;358(2):232-43. https://doi.org/10.1016/j.mce.2012.02.021Test.; Fleisher R., Blanck A., Gustavsson I. et al. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):603-14. https://doi.org/10.1016/j.bpobgyn.2008.01.005Test.; Bestel E., Donnez J. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Rev Endocrinol Metab. 2014;9(1):79-92. https://doi.org/10.1586/17446651.2014.862495Test.; Movarek M.B., Yin P., Ono M. et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21(1):1-12. https://doi.org/10.1093/humupd/dmu048Test.; Spitz I.M. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82(5):442-52. https://doi.org/10.1016/j.contraception.2009.12.012Test.; Uchikawa J., Shiozawa T., Shih H.C. et al. Expression of steroid receptor coactovators and corepressors in human endometrial hyperplasia and carcinoma with relevance ro steroid receptors and Ki-67 expression. Cancer. 2003;98(10):2207-13. https://doi.org/10.1002/cncr.11760Test.; Tristan M., Orozco L.J., Steed A. et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev. 2012;(8):CD007687. https://doi.org/10.1002/14651858.CD007687.pub2Test.; Esteve J.L., Acosta R., Perez Y. et al. Mifepristone versus placebo to trial uterine myoma: a double-blind, randomized clinical trial. Int J Womens Health. 2013;5:361-9. https://doi.org/10.2147/IJWH.S42770Test.; FDA approves ellaTM tablets for prescription emergency contraception. FDA News Room, 2010. Available at: https://www.prnewswire.com/news-releases/fda-approves-ella-tablets-for-prescription-emergency-contraception-100652599.htmlTest.; Williams A., Bergeron C., Barlow D.H, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathology. 2012;31(6):556-69. https://doi.org/10.1097/PGP.0b013e318251035bTest.; Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application. Dublin: Aug. 21, 2018. Available at: https://www.drugs.com/nda/ulipristal_acetate_180821.htmlTest.; EMA/PRAC/459031/2020 Human Medicines Division. Pharmacovigilance Risk Assessment Committee (PRAC). European Medicine Agency: 31.08.2020. Available at: https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-31-august-3-september_en.pdfTest.; FIBRISTAL (ulipristal acetate tablets, 5 mg) - Voluntary withdrawal in Canada due to risk of drug-induced liver injury. Health Canada: 30 September, 2020. Available at: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74063a-eng.phpTest.; National Pharmaceutical Regulatory Agency Esmya (ulipristal acetate 5 mg): Withdrawal of product registration. Ministry of Health Malaysia: 14.12.2020. Available at: https://npra.gov.my/index.php/en/health-professionals/recent-updates/419-english/safety-alerts-main/safety-alerts-2020/1527169-esmya-ulipristal-acetate-5-mg-withdrawal-of-product-registration.htmlTest.; Temporary suspension of sales of Esmya™ (ulipristal acetate) tablet 5 mg. Health Sciences Authority (HSA). A Singapor Government Agency: Sep 2020. Available at: https://www.hsa.gov.sg/announcements/safety-alert/temporary-suspension-of-sales-of-esmyaTest-(ulipristal-acetate)-tablet-5-mg-(sep-2020).; EMA/PRAC/ 593162/2020. Ulipristal acetate for uterine fibroids: EMA recommends restricting use. European Medicine Agency: 13.11.2020. Available at: https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids_en.pdfTest.; Gemzell-Danielsson K., Heikinheimo O., Zatik J. et al. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol. 2020;252:7-14. https://doi.org/10.1016/j.ejogrb.2020.05.043Test.; https://www.gynecology.su/jour/article/view/866Test

الإتاحة: https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.195Test
https://doi.org/10.1016/S1701-2163Test(15)30338-8
https://doi.org/10.1210/jc.2012-3237Test
https://doi.org/10.1097/01.AOG.0000136079.62513.39Test
https://doi.org/10.1289/ehp.5787Test
https://doi.org/10.1111/j.1524-4733.2007.00168.xTest
https://doi.org/10.1002/ijgo.12666Test
https://doi.org/10.1093/humupd/2.4.295Test
https://doi.org/10.2147/IJWH.S50786Test
https://doi.org/10.1155/2013/918179Test

المؤلفون: Felice Petraglia, Marie Madeleine Dolmans

المساهمون: UCL - SSS/IREC/GYNE - Pôle de Gynécologie

المصدر: Fertility and sterility, Vol. 118, no.4, p. 605-606 (2022)

مصطلحات موضوعية: Anemia, Iron-Deficiency, Iron, Obstetrics and Gynecology, Anemia, Iron Deficiencies, heavy menstrual bleeding, reproduction, iron deficiency, Reproductive Health, Reproductive Medicine, Pregnancy, Quality of Life, Humans, Women's Health, Female, Menorrhagia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf1a50dc2bed9fccbee357fdf89227c2Test
https://pubmed.ncbi.nlm.nih.gov/36182259Test

المؤلفون: Miglani, Urvashi, Singh, Pushpa

المصدر: International Journal of Reproduction, Contraception, Obstetrics and Gynecology; Vol 4, No 3 (2015): May-June 2015; 795-800 ; 2320-1789 ; 2320-1770

مصطلحات موضوعية: LNG IUS, Heavy menstrual bleeding, Fibroids, Anemia

وصف الملف: application/pdf

العلاقة: https://www.ijrcog.org/index.php/ijrcog/article/view/2009/1737Test; https://www.ijrcog.org/index.php/ijrcog/article/view/2009Test

الإتاحة: https://doi.org/10.18203/2320-1770.ijrcog20150094Test
https://www.ijrcog.org/index.php/ijrcog/article/view/2009Test